Glenmark Pharmaceuticals Limited Overview
Get informed when a big investor buys or sells
+ Follow17.10%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Glenmark Pharmaceuticals Limited (GLENMARK.NS) currently reports a ROE of 17.1%. That is above the sector sector average of 11.85%. Use the charts on this page to explore Glenmark Pharmaceuticals Limited's ROE history and peer comparisons.
Glenmark Pharmaceuticals Limited's ROE of 17.1% is higher than the its sector sector average of 11.85%. That is roughly 44.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Glenmark Pharmaceuticals Limited's current 17.1% should be judged against industry norms (sector average: 11.85%) and against GLENMARK.NS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 17.1%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.85%. From there, open related valuation or income-statement pages for Glenmark Pharmaceuticals Limited, and consider following GLENMARK.NS for alerts when major investors trade the stock.
